STAT+: Eli Lilly enlists AI startup for next-generation gene editors
Eli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could reshape genetic medicine.
ORIGINAL SOURCE →via STAT News Health
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · tech
- [TECH] Save $400 on this 4K-ready MSI gaming PC with an RTX 5070 Ti and 32GB DDR5 — budget-friendly Aegis Z2 rig also ships with eight-core AMD Ryzen CPU and a 2TB SSD, now just $1,849
- [TECH] Nearly half of London jobs at risk of AI disruption and women will be hardest hit, new report finds
- [TECH] Localsend: An open-source cross-platform alternative to AirDrop
- [TECH] Predicting consequences of new hepatitis B vaccine recs
- [TECH] OpenAI reportedly missed revenue targets. Shares of Oracle and these chip stocks are falling
- [TECH] LangChain 0.2.10 vs. LangSmith 0.12: LLM Chain Debugging Efficiency